Sjögren's Foundation Clinical Practice Guidelines

Ocular Management in Sjögren's Patients

The Sjögren's Foundation has developed the first-ever U.S. Clinical Practice Guidelines for Ocular Management in Sjögren's to ensure quality and consistency of care for the assessment and management of patients.

The Clinical Practice Guidelines for Ocular Management in Sjögren's established that, in a given patient, the clinician must determine whether the dry eye is due to inadequate production of tears, excess evaporation, or a combination of both mechanisms. The success of a treatment option depends upon proper recognition and approach to therapy. For the development of the Sjögren's Foundation Ocular Guidelines, the Report of the International Workshop on Dry Eye (DEWS) was used as a starting point, then panels of eye care providers and consultants evaluated peer-reviewed publications and developed recommendations for evaluation and management of dry eye disease associated with Sjögren's.

Ocular Guidelines Summary and Recommendation:

Evaluation of symptoms can be accomplished by use of a number of questionnaires to grade severity of symptoms. Practical considerations recommend use of three specific questions (Table 1). A number of clinical tests of tear function can be performed in the office setting to quantify the volume and stability of tear function, including tear meniscus height and rapid tear film breakup time (TFBUT). Determination of tear secretion rate is

the most helpful way to differentiate aqueous-deficient dry eye from evaporative dry eye, and this is usually accomplished by the Schirmer test. More advanced diagnosis of dry eye can be achieved by measuring tear film osmolarity, which can also be used to monitor response to therapy. Evaluation of lid blink function and health of the eyelid margin, particularly the meibomian glands, is necessary to quantify evaporative dry eye. Evaluation of the severity of dry eye disease is possible with application of topical dyes, including fluorescein, rose bengal, and lissamine green, to quantify damage to the ocular surface.

Management of dry eye depends upon the nature of the dry eye and the severity of symptoms. The algorithm presented in Figure 1 details the options available. In early disease,

tear replacement with topically applied artificial tear or lubricant solutions may be sufficient, but progressive or more severe inflammation of the lacrimal gland and ocular surface occur both as an inciting event in many cases and as a secondary effect as the dry eye disease worsens, called keratoconjunctivitis sicca (KCS), requires the use of dietary supplements (omega 3 essential fatty acids), anti-inflammatory measures (e.g., topical corticosteroids or cyclosporine), or oral secretagogues.

Plugging of the lacrimal puncta can be done once the inflammatory component of dry eye is controlled. Control of lid margin (meibomian gland) disease may require topical antibiotic or systemic doxycycline therapy. The most severe cases of dry eye, particularly those unresponsive to more standard therapy, may require use of topical autologous serum or partial closure of the interpalpebral fissure to reduce surface exposure. Scleral contact lenses may be needed to control severe ocular surface damage.

Dry eye may signal the presence of Sjögren's, particularly when it is associated with inflammation, difficulty in management, or dry mouth. A patient with suspected Sjögren's should be referred to a dentist for oral disease prevention/management and to a rheumatologist for systemic treatment.

Table 1 – Screening Questions for Dry Eye

Key screening questions for dry eye disease

A patient reporting '**Yes**' to any of the following warrants a full ocular examination

How often do your eyes feel dryness, discomfort, or irritation? Would you say it is often or constantly? **(Y/N)**

When you have eye dryness, discomfort, or irritation, does this impact your activities (e.g. do you stop or reduce your time doing them)? (Y/N)

Do you think you have dry eye? (Y/N)



Figure 1: Treatment Algorithm Based Upon Severity Level and Response to Therapy

good good good good good good good good	Diagnosis Treatment Severity Level 1 ¹ S	Treatment Severity Level 1 ¹	Severity Level 2	Severity Level 3	Severity Level 4	Evidence ²	Recommendation ³
* • Onnega 3 essential fatty acid supplement * • Anti-inflammatory threapy: Octosponine * • Anti-inflammatory threapy: Octosponine * • Anti-inflammatory threapy: Octosponine * • Secretagegues * Secretagegues * Feducation and environment diet modification • Feducation and environment diet modification • Feducation and environment diet modification • Education and environment diet modification • Feducation and environment purcha londerate • Moisture chamber spectacles • Moisture chamber spectacles • Moisture chamber spectacles • Moisture chamber spectacles • Feducation and environment purcha londerate • Feducation and environment purchased in insufficient • Feducation and environment purchased in insufficient insufficient insufficient insufficient insufficient insufficien	Dry eye disease – Aqueous deficiency		/diet modification temic medication its			poos poos	STRONG STRONG STRONG
• Topical autologous serum • Contact lenses • Permanent puntral occlusion • Education and environment/diet modification • Equitation of finefuling systemic medication • Equitation of finefuling systemic medication • Epield surgery • Comega 3 essential fatty acid supplement • Anti-inflammatory therapy: Cyclospointe • Perceible corl doxy-cytine • Expression of melbornian glands • Perceible corl doxy-cytine • Expression of melbornian glands • Condact lenses • Moisture chamber spectacles • Moisture chamber spectacles • Moisture chamber spectacles • Moisture chamber spectacles • Permanent puntral compression) • Insufficient • (Upinition pulsed thermal compression) • Insufficient • (Probing of melbornian gland) • Everlia surgery • Permanent purple surgery • Permanent puntral compression) • Insufficient • (Probing of melbornian gland) • Everlia surgery • (Probing of melbornian gland) • Everlia surgery • Permanent purple surgery • Permanent purple surgery • Permanent puntral compression) • Permanent puntral compression • Permanent punt	gland disease		Omega 3 essential fatty aci Anti-inflammatory therapy Anti-inflammatory therapy Punctal plugs Secretagogues Moisture chamber spectac	id supplement r. cyclosporine r. pulse steroids les		moderate good good good good	MODERATE STRONG MODERATE STRONG MODERATE STRONG MODERATE STRONG MODERATE STRONG
Education and environment/dilet modification Education and environment/dilet modification Education and environment/dilet modification Elimination of offending systemic medication To mega 3 essential fatty acid supplement Anti-inflammatory therapy: cyclosporine Anti-inflammatory therapy: cyclosporine Anti-inflammatory therapy: cyclosporine Sporical authorycine Expression of meibomian glands Expression of meibomian glands Expression of meibomian glands Moisture chamber spectacles Permanent purctal occlusion Everlagogues Permanent purctal occlusion Insufficient Perpension of meibomian gland) Insufficient Perpension of meibomian glands Permanent purctal occlusion Everlagogues Everlagogues Everlagogues Everlagogues Everlagogues				Topical autologous serum Contact lenses Permanent punctal occlusic	uc	poos poos	MODERATE STRONG MODERATE STRONG MODERATE STRONG
Education and environment/diet modification Elimination of offending systemic medication Elimination of offending systemic medication Adrificial tears with lipid component • Adrificial tears with lipid component • Conega 3 essential fatty acid supplement • Anti-inflammatory therapy: cyclosporine • Anti-inflammatory therapy: pulse steroids • Topical azithromycin • Liposomal stray of tears or the steroids • Possible oral doxycycline • Expression of meibomian glands • Possible oral doxycycline • Foretagogues • Secretagogues • Moisture chamber spectacles • Moisture chamber spectacles • Moisture chamber spectacles • Permanent punctal coccusion • Orbital surrection of meibomian glands • Permanent punctal coccusion • Permanent punctal coccusion or punctal pu					 Systemic anti-inflammatory medication Eyelid surgery 	moderate good	DISCRETIONARY MODERATE STRONG
Education and environment/diet modification e Elimination of offending systemic medication e Elimination of offending systemic medication e Elimination of offending systemic medication e Artificial tears with lipid component e Anti-inflation and a sessential fatty acid supplement e Onega 3 essential fatty acid supplement e Anti-inflation and ory therapy: cyclospoine e Anti-inflation and ory therapy: cyclospoine e Anti-inflation and ory therapy: pulse steroids e Topical azithromycin e Expression of meibomian glands e Porsible oral doxycycline e Expression of meibomian glands e Secretagogues e Good e Contact lenses e Moisture chamber spectacles e Permanent purctal occlusion e (Lipiflow pulsed thermal compression) insufficient e (Probing of meibomian gland) e Evelid surgery e Evelid surgery e Evelid surgery eood							
• Omega 3 essential fatty acid supplement • Anti-inflammatory therapy: cyclosporine • Anti-inflammatory therapy: pulse steroids • Anti-inflammatory therapy: pulse steroids • Anti-inflammatory therapy: pulse steroids • Topical azithromycin • Liposomal spray • Possible oral doxycycline • Expression of meibomian glands • Punctal plugs • Punctal plugs • Secretagogues • Moisture chamber spectacles • Moisture chamber spectacles • Permanent punctal coclusion • Contact lenses • Permanent punctal coclusion • (Lipiflow pulsed thermal compression) insufficient • (Probing of meibomian gland) • Experience anti-inflammatory medication moderate • Experience anti-inflammatory medication proderate proderate • Experience anti-inflammatory medication proderate proderate • Experience anti-inflammatory medication proderate	Dry eye disease – Aqueous deficiency with meibomian	 Education and environment Elimination of offending sys Artificial tears with lipid corr Eyelid therapy: warm compr 	/diet modification temic medication pponent ess, massage			poos s	STRONG STRONG STRONG STRONG
	gland disease		Omega 3 essential fatty aci Anti-inflammatory therapy Anti-inflammatory therapy Anti-inflammatory therapy Topical azithromycin Liposomal spray Possible oral doxycycline Expression of meibomian g Punctal plugs Secretagogues Moisture chamber spectac			moderate good good good good good good good insufficient insufficient moderate good	MODERATE STRONG



The Sjögren's Foundation Clinical Practice Guidelines Committee (CPGC): Gary N. Foulks, MD, FACS, S. Lance Forstot, MD, FACS, Peter C. Donshik, MD, Joseph Z. Forstot, MD, FACP, FACR, Michael H. Goldstein, MD, MM, Michael A. Lemp, MD, J. Daniel Nelson, MD, FACS, Kelly K. Nichols, OD, MPH, PHD, Stephen C. Pflugfelder, MD, Jason M. Tanzer, DMD, PHD, Penny Asbell, MD, MBA, FACS, FOUNDATION Katherine Hammitt, MA, and Deborah S. Jacobs, MD

This information was taken from the Journal of the American Dental Association (JADA). Please visit www.sjogrens.org to find the most updated information about the Sjögren's Foundation Clinical Practice Guidelines and be sure to talk to your physician about them.

www.sjogrens.org